The goal of this project is to evaluate the efficacy of amantadine and propranolol for the treatment of cocaine pendence in patients who present with severe cocaine withdrawal symptoms, as measured by scores on the Cocaine Selective Severity Assessment (CSSA), and have trouble initiating abstinence from cocaine. The initiation of abstinence in outpatient cocaine dependence treatment can be difficult. Treatment dropout rates are high and many patients continue to use cocaine. Preliminary data from our Center suggest that patients with high scores on the CSSA at treatment entry are much more prone to dropout and are less likely to achieve abstinence during the first several weeks of treatment. Amantadine is an indirect dopamine agonist that has been shown to be able to reduce dysphoria during early cocaine abstinence. In a recent double- blind trial, arnantadine was able to improve abstinence rates in a subgroup of patients with high CSSA scores at baseline. Among patient with initial CSSA scores above the 67th percentile, those treated with arnantadine submitted 50% benzoylecgonine-negative urines throughout the 4 week trial, whereas placebo treated patients submitted only 8% benzoylecgonine-negative urines. Propranolol is a beta adrenergic blocker that may be capable of reducing autonomic arousal associated with cocaine craving during early abstinence. In a recent trial, patients with high baseline CSSA scores treated with propranolol were significantly more likely to be retained in treatment than placebo treated patients (75% vs. 35%). Propranolol treated patients with high baseline CSSA scores also had significantly lower urinary benzoylecgonine levels during the 8 week trial than did placebo-treated, high CSSA patients. Amantadine, propranolol and the combination of the two medications will be evaluated in an 8 week, double-blind, placebo-controlled trial. For this trial, we will select cocaine dependent outpatients with high CSSA scores at intake who demonstrate a poor response to treatment by continuing to use cocaine during a two week baseline evaluation period. Continued use will be determined by two urine toxicology screens positive for benzoylecgonine during the 2 week baseline. Treatrnent will include weekly individual cognitive behavioral relapse prevention psychotherapy. Outcome measures will include quantitative urinary benzoylecgonine levels, self-reported cocaine use by timeline followback, and results from the Addiction Severity Index.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
1P50DA012756-01
Application #
6224619
Study Section
Special Emphasis Panel (ZDA1-KXA-N (27))
Project Start
1999-09-30
Project End
2004-08-31
Budget Start
Budget End
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Wang, Ze; Suh, Jesse; Duan, Dingna et al. (2017) A hypo-status in drug-dependent brain revealed by multi-modal MRI. Addict Biol 22:1622-1631
Runarsdottir, Valgerdur; Hansdottir, Ingunn; Tyrfingsson, Thorarinn et al. (2017) Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial. J Addict Med 11:197-204
Wang, Ze; Suh, Jesse; Li, Zhengjun et al. (2015) A hyper-connected but less efficient small-world network in the substance-dependent brain. Drug Alcohol Depend 152:102-8
Kampman, Kyle M; Lynch, Kevin G; Pettinati, Helen M et al. (2015) A double blind, placebo controlled trial of modafinil for the treatment of cocaine dependence without co-morbid alcohol dependence. Drug Alcohol Depend 155:105-10
Clarke, Toni-Kim; Weiss, Amy R D; Ferarro, Thomas N et al. (2014) The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction. Ann Hum Genet 78:33-9
Pettinati, Helen M; Kampman, Kyle M; Lynch, Kevin G et al. (2014) A pilot trial of injectable, extended-release naltrexone for the treatment of co-occurring cocaine and alcohol dependence. Am J Addict 23:591-7
Young, Kimberly A; Franklin, Teresa R; Roberts, David C S et al. (2014) Nipping cue reactivity in the bud: baclofen prevents limbic activation elicited by subliminal drug cues. J Neurosci 34:5038-43
Magland, Jeremy F; Childress, Anna Rose (2014) Task-correlated facial and head movements in classifier-based real-time FMRI. J Neuroimaging 24:371-8
Clarke, Toni-Kim; Bloch, Paul J; Ambrose-Lanci, Lisa M et al. (2013) Further evidence for association of polymorphisms in the CNR1 gene with cocaine addiction: confirmation in an independent sample and meta-analysis. Addict Biol 18:702-8
Clarke, Toni-Kim; Crist, Richard C; Kampman, Kyle M et al. (2013) Low frequency genetic variants in the ?-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine. Neurosci Lett 542:71-5

Showing the most recent 10 out of 56 publications